Bloomberg Markets
Reckitt Sales Hit by Lackluster US Demand for Cold Medicines
Most Important Insight
Reckitt Benckiser's recovery is stalled by a significant underperformance in its high-margin Health division, where a weak US cold and flu season led to a 0.5% growth rate against a 2.3% forecast.
Most Original Insight
The Nutrition segment, despite being the center of a $600 million legal verdict, showed unexpected resilience with a decline of only 0.9% compared to the 3.5% drop anticipated by analysts.
Key Points
- Reckitt reported first-quarter 2026 like-for-like sales growth of 1.5%, missing the 2.1% analyst consensus.
- The Health unit's 0.5% growth was a major miss compared to the 2.3% estimate, attributed to low demand for Mucinex in the US.
- Hygiene sales grew by 3.1%, exceeding the 2.2% estimate due to strong performance from Finish and Lysol.
- Nutrition sales fell 0.9%, a significantly better outcome than the 3.5% decline predicted by the market.
- CEO Kris Licht is currently conducting a strategic review of the company's portfolio for potential non-core brand disposals.
- The company faces significant legal headwinds following a $600 million US jury verdict in March 2026 regarding its Enfamil baby formula.
- Reckitt maintained its full-year 2026 revenue growth guidance of 1% to 3% despite the weak start in the Health segment.
- Management is attempting to restore investor confidence following an accounting scandal in the Middle East and ongoing litigation.
Investment Implications
| Asset / Sector / Instrument | Action | Source | Notes |
|---|---|---|---|
| Consumer Staples (Hygiene) | BUY | implicit | The 3.1% growth in the Hygiene unit suggests strong pricing power and demand for core brands like Lysol and Finish. |
| Reckitt Benckiser Group Plc | HOLD | implicit | The company missed Q1 sales targets and faces a $600 million legal verdict, though Hygiene remains a bright spot. |
| Consumer Healthcare Sector | SELL | implicit | Weak demand for cold and flu medicines in the US suggests a broader volume headwind for over-the-counter drug manufacturers. |
Hang on a sec…
- The claim that maintaining full-year guidance is feasible seems optimistic given the Health unit missed its quarterly growth target by nearly 80%.
- The article frames a 0.9% decline in Nutrition as a positive result, potentially downplaying the long-term brand damage from the Enfamil litigation.
- Attributing the Health miss solely to a 'lackluster' flu season ignores potential market share gains by competitors like Kenvue or Haleon.